GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719320 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway | 202/7305 | 288/18723 | 4.64e-27 | 1.73e-24 | 202 |
GO:000640318 | Oral cavity | OSCC | RNA localization | 150/7305 | 201/18723 | 6.90e-25 | 1.98e-22 | 150 |
GO:200124220 | Oral cavity | OSCC | regulation of intrinsic apoptotic signaling pathway | 123/7305 | 164/18723 | 5.71e-21 | 9.77e-19 | 123 |
GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
GO:004348420 | Oral cavity | OSCC | regulation of RNA splicing | 108/7305 | 148/18723 | 4.25e-17 | 3.69e-15 | 108 |
GO:200123420 | Oral cavity | OSCC | negative regulation of apoptotic signaling pathway | 148/7305 | 224/18723 | 1.71e-16 | 1.36e-14 | 148 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:200124320 | Oral cavity | OSCC | negative regulation of intrinsic apoptotic signaling pathway | 73/7305 | 98/18723 | 9.33e-13 | 4.22e-11 | 73 |
GO:007233120 | Oral cavity | OSCC | signal transduction by p53 class mediator | 107/7305 | 163/18723 | 4.75e-12 | 1.83e-10 | 107 |
GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
GO:000863018 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway in response to DNA damage | 72/7305 | 99/18723 | 9.50e-12 | 3.50e-10 | 72 |
GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
GO:200102017 | Oral cavity | OSCC | regulation of response to DNA damage stimulus | 131/7305 | 219/18723 | 3.21e-10 | 8.72e-09 | 131 |
GO:007233219 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway by p53 class mediator | 56/7305 | 76/18723 | 8.43e-10 | 2.13e-08 | 56 |
GO:004277118 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 36/7305 | 43/18723 | 2.12e-09 | 4.97e-08 | 36 |
GO:00063547 | Oral cavity | OSCC | DNA-templated transcription, elongation | 63/7305 | 91/18723 | 4.86e-09 | 1.07e-07 | 63 |
GO:00310567 | Oral cavity | OSCC | regulation of histone modification | 94/7305 | 152/18723 | 9.57e-09 | 1.99e-07 | 94 |
GO:00427707 | Oral cavity | OSCC | signal transduction in response to DNA damage | 102/7305 | 172/18723 | 5.27e-08 | 9.68e-07 | 102 |
GO:190179620 | Oral cavity | OSCC | regulation of signal transduction by p53 class mediator | 62/7305 | 93/18723 | 5.99e-08 | 1.09e-06 | 62 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF3 | SNV | Missense_Mutation | | c.116N>G | p.Ala39Gly | p.A39G | P17036 | protein_coding | tolerated(0.06) | benign(0.116) | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ZNF3 | insertion | In_Frame_Ins | novel | c.1181_1182insTGCTGTTTTGTTTCATGATTTCGTTAATTATGGAAATTT | p.Asn394_Pro395insAlaValLeuPheHisAspPheValAsnTyrGlyAsnPhe | p.N394_P395insAVLFHDFVNYGNF | P17036 | protein_coding | | | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
ZNF3 | insertion | Frame_Shift_Ins | novel | c.275_276insAACTTCAGACC | p.Glu93ThrfsTer48 | p.E93Tfs*48 | P17036 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ZNF3 | insertion | In_Frame_Ins | novel | c.273_274insGAATGTAGCAAGAGCTTTAAT | p.Asp91_Arg92insGluCysSerLysSerPheAsn | p.D91_R92insECSKSFN | P17036 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ZNF3 | SNV | Missense_Mutation | | c.481G>A | p.Glu161Lys | p.E161K | P17036 | protein_coding | tolerated(0.62) | benign(0.13) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | rs199648870 | c.632N>A | p.Arg211Gln | p.R211Q | P17036 | protein_coding | tolerated(0.92) | benign(0.109) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | novel | c.496C>T | p.Pro166Ser | p.P166S | P17036 | protein_coding | tolerated(0.2) | benign(0.081) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | | c.1247G>T | p.Arg416Ile | p.R416I | P17036 | protein_coding | deleterious(0) | benign(0.31) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF3 | SNV | Missense_Mutation | novel | c.180C>A | p.Phe60Leu | p.F60L | P17036 | protein_coding | tolerated(0.43) | benign(0.019) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ZNF3 | SNV | Missense_Mutation | novel | c.1237C>T | p.Arg413Cys | p.R413C | P17036 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |